These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 37499179)

  • 1. Kratom use disorder: case reports on successful treatment with home induction of buprenorphine-naloxone.
    Kiyokawa M; Kwon AK; Cape MC; Streltzer JM
    Fam Pract; 2023 Nov; 40(4):596-598. PubMed ID: 37499179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of kratom dependence with buprenorphine/naloxone in a veteran population.
    Lei J; Butz A; Valentino N
    Subst Abus; 2021; 42(4):497-502. PubMed ID: 33617752
    [No Abstract]   [Full Text] [Related]  

  • 3. A Complex Case of Kratom Dependence, Depression, and Chronic Pain in Opioid Use Disorder: Effects of Buprenorphine in Clinical Management.
    Bowe A; Kerr PL
    J Psychoactive Drugs; 2020; 52(5):447-452. PubMed ID: 32546067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term buprenorphine treatment for kratom use disorder: A case series.
    Broyan VR; Brar JK; Allgaier Student T; Allgaier JT
    Subst Abus; 2022; 43(1):763-766. PubMed ID: 35112990
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment of Kratom Withdrawal and Dependence With Buprenorphine/Naloxone: A Case Series and Systematic Literature Review.
    Weiss ST; Douglas HE
    J Addict Med; 2021 Apr; 15(2):167-172. PubMed ID: 32858563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of Kratom Dependence With Buprenorphine-Naloxone Maintenance.
    Buresh M
    J Addict Med; 2018; 12(6):481-483. PubMed ID: 29944481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Buprenorphine-Naloxone in the Setting of Kratom Withdrawal, Opioid Use Disorder, and Stage IV Lung Adenocarcinoma.
    Hong S; Zimmerman PE; Rao V; Markwalter DW
    J Palliat Med; 2023 May; 26(5):734-736. PubMed ID: 36580544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Home induction and outpatient treatment of kratom use disorder with buprenorphine-naloxone: A case report in a young adult.
    Schmuhl KK; Gardner SM; Cottrill CB; Bonny AE
    Subst Abus; 2020; 41(3):311-314. PubMed ID: 31644379
    [No Abstract]   [Full Text] [Related]  

  • 9. A Case of Potential Pharmacokinetic Kratom-drug Interactions Resulting in Toxicity and Subsequent Treatment of Kratom Use Disorder With Buprenorphine/Naloxone.
    Brogdon HD; McPhee MM; Paine MF; Cox EJ; Burns AG
    J Addict Med; 2022 Sep-Oct 01; 16(5):606-609. PubMed ID: 35165231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of Kratom Withdrawal and Addiction With Buprenorphine.
    Khazaeli A; Jerry JM; Vazirian M
    J Addict Med; 2018; 12(6):493-495. PubMed ID: 30383616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Need for clarity and context in case reports on kratom use, assessment, and intervention.
    Smith KE; Dunn KE; Epstein DH; Feldman JD; Garcia-Romeu A; Grundmann O; Henningfield JE; McCurdy CR; Rogers JM; Schriefer D; Singh D; Weiss ST
    Subst Abus; 2022; 43(1):1221-1224. PubMed ID: 35657649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kratom and opioid use disorder in the perioperative period: A case report on the expanding role of buprenorphine.
    Perez J
    J Opioid Manag; 2023; 19(1):91-93. PubMed ID: 36683304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low dose IV buprenorphine inductions for patients with opioid use disorder and concurrent pain: a retrospective case series.
    Murray JP; Pucci G; Weyer G; Ari M; Dickson S; Kerins A
    Addict Sci Clin Pract; 2023 Jun; 18(1):38. PubMed ID: 37264449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 48-hour Induction of Transdermal Buprenorphine to Sublingual Buprenorphine/Naloxone: The IPPAS Method.
    Azar P; Wong JSH; Mathew N; Vogel M; Perrone J; Herring AA; Krausz RM; Montaner JSG; Greenwald MK; Maharaj AR
    J Addict Med; 2023 Mar-Apr 01; 17(2):233-236. PubMed ID: 36149002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population.
    Morgan JR; Schackman BR; Leff JA; Linas BP; Walley AY
    J Subst Abuse Treat; 2018 Feb; 85():90-96. PubMed ID: 28733097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Flexible Buprenorphine/Naloxone Model of Care for Reducing Opioid Use in Individuals With Prescription-Type Opioid Use Disorder: An Open-Label, Pragmatic, Noninferiority Randomized Controlled Trial.
    Jutras-Aswad D; Le Foll B; Ahamad K; Lim R; Bruneau J; Fischer B; Rehm J; Wild TC; Wood E; Brissette S; Gagnon L; Fikowski J; Ledjiar O; Masse B; Socias ME;
    Am J Psychiatry; 2022 Oct; 179(10):726-739. PubMed ID: 35702828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful Buprenorphine/Naloxone Low-dose Induction in Pregnancy: A Case Report.
    Coish R; Hardial J
    J Addict Med; 2023 Jan-Feb 01; 17(1):114-116. PubMed ID: 35916416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unobserved versus observed office buprenorphine/naloxone induction: a pilot randomized clinical trial.
    Gunderson EW; Wang XQ; Fiellin DA; Bryan B; Levin FR
    Addict Behav; 2010 May; 35(5):537-40. PubMed ID: 20106601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid Micro-induction of Buprenorphine/Naloxone for Opioid Use Disorder in a Critically ill Intubated Patient: A Case Report.
    Hamata B; Griesdale D; Hann J; Rezazadeh-Azar P
    J Addict Med; 2020 Dec; 14(6):514-517. PubMed ID: 32649330
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.